SAH & Aneurysm Management
SAH & Aneurysm Management
What Do You Need to Know?
- ISAT trial: coiling superior to clipping for anterior circulation ruptured aneurysms amenable to both; lower death/dependency at 1 year but higher retreatment rates
- Timing: secure aneurysm early (<24 hours, ideally <12 hours) to prevent rebleeding; rebleeding risk is highest in the first 24 hours (~4–6%)
- Vasospasm peaks days 4–14; nimodipine 60 mg PO q4h × 21 days is the only proven agent; endovascular rescue (intra-arterial vasodilators, balloon angioplasty) for refractory cases
- Unruptured aneurysms: ISUIA data guides management — treat ≥7 mm anterior, ≥5 mm posterior, or symptomatic/growing; PHASES score predicts 5-year rupture risk
- Spetzler-Martin grade guides AVM surgical risk (size + eloquence + deep venous drainage); ARUBA trial favors medical management for unruptured AVMs
- Flow diverters (Pipeline) are indicated for large/giant, wide-neck, or fusiform aneurysms not amenable to standard clipping or coiling
Clipping vs. Coiling: Landmark Trials
ISAT Trial (International Subarachnoid Aneurysm Trial, 2002)
- Design: Largest RCT comparing surgical clipping vs. endovascular coiling — 2,143 patients with ruptured aneurysms amenable to either treatment
- Population: Predominantly anterior circulation (~97%); good clinical grade (WFNS I–II in ~88%)
- Primary endpoint: Death or dependency (modified Rankin Scale 3–6) at 1 year
| Outcome | Coiling | Clipping | Significance |
|---|---|---|---|
| Death or dependency at 1 year | 23.7% | 30.6% | RRR 23.5%; ARR ~7%; NNT ~14; p = 0.0019 |
| Rebleeding at 10 years | 2.9% | 0.9% | Higher with coiling (incomplete occlusion) |
| Retreatment rate | ~17% | ~4% | Significantly higher with coiling |
| Seizures at 1 year | Lower | Higher | Craniotomy increases seizure risk |
| Survival benefit | Maintained at 7-year and 18-year follow-up | ||
- Bottom line: Coiling preferred when both options are technically feasible; survival benefit is durable but retreatment rates are higher with coiling
- Limitation: Mostly anterior circulation, good-grade patients; does not apply to all aneurysm anatomies
BRAT Trial (Barrow Ruptured Aneurysm Trial, 2012)
- Design: Randomized all SAH patients regardless of aneurysm anatomy; crossover from coil to clip was allowed if coiling was not feasible
- 1-year results: No significant difference in poor outcome (mRS 3–6) between groups overall
- 6-year results: Similar long-term outcomes; higher retreatment rate with coiling
- Key findings by location:
- Posterior circulation aneurysms: Better outcomes with coiling
- MCA aneurysms: Better outcomes with clipping (higher crossover rate from coil to clip)
- Bottom line: Long-term outcomes are similar; treatment choice should be individualized by aneurysm anatomy and location
Board Pearls
- ISAT = coiling superior for ruptured aneurysms amenable to both treatments (anterior circulation, good grade) — 23.5% relative risk reduction in death/dependency at 1 year
- BRAT = similar long-term outcomes but confirmed MCA favors clipping and posterior circulation favors coiling
- Coiling has higher retreatment rates (~17% vs. ~4%) and higher late rebleeding (~2.9% vs. 0.9% over 10 years)
Factors Favoring Clipping vs. Coiling
Decision-Making Framework
| Factor | Favors Clipping | Favors Coiling |
|---|---|---|
| Location | MCA bifurcation (easily accessible, broad-necked) | Posterior circulation (basilar tip, PICA); cavernous ICA |
| Neck morphology | Wide neck (dome:neck ratio <2) | Narrow neck (dome:neck ratio ≥2) |
| Branch vessels | Branches arising from aneurysm dome or neck | No critical branches incorporated |
| Age | Younger patients (longer durability needed) | Elderly patients (lower procedural morbidity) |
| Surgical risk | Good surgical candidate, low H&H grade | High surgical risk, poor clinical grade |
| Associated hematoma | Large intraparenchymal hematoma requiring evacuation | No mass-occupying hematoma |
| Retreatment concern | Lower retreatment rate (~4%) | Higher retreatment rate (~17%); requires imaging follow-up |
| Antiplatelet need | No antiplatelet requirement post-procedure | Stent-assisted coiling requires dual antiplatelet therapy |
Adjunctive Endovascular Techniques
Balloon-Assisted Coiling
- Temporary balloon inflation across aneurysm neck during coil placement to prevent coil herniation
- Useful for wide-necked aneurysms that cannot be coiled with simple technique
- No long-term antiplatelet requirement
Stent-Assisted Coiling
- Intracranial stent deployed across aneurysm neck as scaffold to retain coils
- Requires dual antiplatelet therapy (aspirin + clopidogrel) — challenging in acute SAH setting due to potential need for EVD or additional surgery
- Better for wide-necked aneurysms not amenable to simple or balloon-assisted coiling
Flow Diverters (Pipeline Embolization Device)
- Dense-mesh stent placed across aneurysm neck → redirects flow away from aneurysm sac → progressive thrombosis and endothelialization
- Indications: Large (≥10 mm) or giant (≥25 mm) aneurysms, wide-necked aneurysms, fusiform aneurysms, blister aneurysms
- Best for: ICA (paraclinoid/ophthalmic segment) aneurysms; increasingly used in other locations
- Requires dual antiplatelet therapy for 3–6 months, then aspirin long-term
- Complications: Delayed aneurysm rupture (~1–3%), perforator infarction, in-stent stenosis/thrombosis
- Aneurysm occlusion occurs over weeks to months (not immediate) — not ideal for acutely ruptured aneurysms unless no other option
Clinical Pearl
MCA aneurysms = clipping; basilar tip = coiling. This is the single most tested surgical decision point. MCA aneurysms have broad necks, incorporate branches, and are surgically accessible via Sylvian fissure. Basilar tip aneurysms are deep, surgically hazardous, and technically ideal for endovascular access. Flow diverters are reserved for large/giant or fusiform aneurysms where standard treatment fails.
Timing of Intervention
Rebleeding Risk
- Rebleeding is the most feared early complication of aneurysmal SAH — carries ~70% mortality
- First 24 hours: 4–6% rebleeding risk (highest risk period)
- Days 2–14: ~1–2% per day if aneurysm is unsecured
- Without treatment: ~20% rebleed within 14 days; ~50% within 6 months
- Risk factors for rebleeding: Higher clinical grade, larger aneurysm, sentinel bleed, uncontrolled hypertension, coagulopathy
Timing Recommendations
| Timing Window | Rationale | Guideline Support |
|---|---|---|
| Ultra-early (<12 hours) | Increasingly favored; greatest reduction in rebleed risk; emerging data supports improved outcomes | Supported by observational studies; not yet mandated by guidelines |
| Early (<24 hours) | Standard of care; substantially reduces rebleeding; allows earlier aggressive vasospasm management | AHA/ASA Class I recommendation |
| <72 hours | Acceptable when <24h is not feasible; still reduces rebleed risk vs. delayed treatment | Generally accepted minimum standard |
| Delayed (>72 hours) | Historical approach; now associated with worse outcomes from rebleeding during wait period | No longer recommended except in select cases (severe medical instability) |
- Key principle: Early securing enables aggressive induced hypertension for vasospasm without fear of rebleeding
- Antifibrinolytic bridge: Aminocaproic acid or tranexamic acid for <72 hours if there is an unavoidable delay (AHA/ASA Class IIa); do NOT use long-term (increases DVT, hydrocephalus)
- Pre-intervention BP target: SBP <160 mmHg until aneurysm is secured; nicardipine infusion preferred
Board Pearls
- Secure the aneurysm within 24 hours (ideally <12 hours) — this is the standard of care
- Rebleeding peaks in the first 24 hours (~4–6%) and carries ~70% mortality
- Short-term TXA or aminocaproic acid is an acceptable bridge but NOT for prolonged use (thrombotic complications)
- Early treatment enables aggressive BP augmentation for vasospasm management
Vasospasm Management Requiring Intervention
Timeline & Risk Factors
- Angiographic vasospasm: Occurs in ~70% of SAH patients; clinically significant (symptomatic) in ~30%
- Timeline: Onset day 3; peak days 7–10; resolves by day 14–21
- Mnemonic: “4–14 rule” — vasospasm window is days 4–14
- Risk factors: Thick clot burden (Modified Fisher 3–4), higher Hunt & Hess grade, smoking, cocaine use, younger age
- Delayed cerebral ischemia (DCI): The clinically meaningful endpoint — new neurological deficit or new infarct attributable to vasospasm after excluding other causes
Medical Management
Nimodipine (The Only Proven Agent)
- Dosing: 60 mg PO (or enteral tube) every 4 hours for 21 days — start on admission, do NOT wait for vasospasm
- Mechanism: Neuroprotective (neuronal calcium channel blockade) rather than preventing large-vessel vasospasm — does NOT significantly reduce angiographic vasospasm but improves functional outcomes
- Evidence: Pickard et al. (1989) — reduced cerebral infarction and poor outcome; remains the only Class I recommendation for vasospasm prevention
- If hypotension: Reduce to 30 mg q2h; do NOT discontinue nimodipine
- IV nimodipine is NOT available in the US — NEVER give oral tablets intravenously (fatal hypotension and cardiac arrest)
Induced Hypertension (Current Standard)
- Replaces historical “Triple-H therapy” (Hypertension, Hypervolemia, Hemodilution)
- Hypervolemia and hemodilution are no longer recommended — no proven benefit; increase pulmonary edema and dilutional anemia
- Euvolemia is the goal; induced hypertension is applied when symptomatic vasospasm develops (after aneurysm is secured)
- Agents: Phenylephrine or norepinephrine infusion; target SBP 180–220 mmHg (individualized to clinical response)
- If neurological deficit improves with BP augmentation → confirms symptomatic vasospasm
Endovascular Rescue Therapies
- Indications: Symptomatic vasospasm refractory to maximal medical management (induced hypertension + euvolemia + nimodipine)
| Technique | Mechanism | Advantages | Limitations |
|---|---|---|---|
| Intra-arterial vasodilators | Verapamil, nicardipine, or milrinone injected directly into spastic vessel | Can treat distal vasospasm; repeatable | Transient effect (hours); may need multiple sessions; systemic hypotension risk |
| Balloon angioplasty | Mechanical dilation of narrowed proximal arteries | More durable effect than pharmacologic vasodilators; immediate luminal improvement | Only for proximal, accessible vessels (ICA, M1, A1, basilar, vertebral); vessel rupture risk ~1–4%; cannot reach distal branches |
- Combined approach: Balloon angioplasty for proximal spasm + intra-arterial vasodilators for distal spasm
- Timing is critical — intervention is most effective before established infarction occurs
Board Pearls
- Nimodipine is the ONLY medication proven to improve outcomes after SAH — 60 mg PO q4h × 21 days; it is neuroprotective, NOT a vasospasm preventer
- Triple-H therapy is outdated — only induced hypertension is recommended; maintain euvolemia
- Endovascular rescue is reserved for medically refractory symptomatic vasospasm — balloon angioplasty is more durable but carries vessel rupture risk
- Vasospasm peaks days 7–10 (4–14 rule); thick SAH + IVH (Modified Fisher 4) carries highest risk
Unruptured Aneurysm Management
ISUIA Trial (International Study of Unruptured Intracranial Aneurysms, 2003)
- Largest prospective study of unruptured aneurysm natural history (4,060 patients)
- Key finding: Rupture risk depends on size AND location — posterior circulation and PCom aneurysms rupture at higher rates at every size
5-Year Cumulative Rupture Rates
| Aneurysm Size | Anterior Circulation (no prior SAH) | Posterior Circulation & PCom |
|---|---|---|
| <7 mm | ~0% | ~2.5–3.4% |
| 7–12 mm | ~2.6% | ~14.5% |
| 13–24 mm | ~14.5% | ~18.4% |
| ≥25 mm (giant) | ~40% | ~50% |
- Critical caveat: Most aneurysms that rupture in clinical practice are <10 mm — ISUIA likely underestimated small aneurysm risk due to selection bias (higher-risk patients were preferentially treated)
- Prior SAH from a different aneurysm increases rupture risk of remaining aneurysms (~1.5% for <7 mm anterior vs. ~0% without prior SAH)
PHASES Score
- Validated risk calculator predicting 5-year rupture risk of unruptured intracranial aneurysms
| Component | Variable | Points |
|---|---|---|
| P — Population | North American / European | 0 |
| Japanese | 3 | |
| Finnish | 5 | |
| H — Hypertension | Yes | 1 |
| A — Age | ≥70 years | 1 |
| S — Size | <7 mm | 0 |
| 7.0–9.9 mm | 3 | |
| 10.0–19.9 mm | 6 | |
| ≥20 mm | 10 | |
| E — Earlier SAH | Prior SAH from a different aneurysm | 1 |
| S — Site | ICA | 0 |
| MCA | 2 | |
| ACA / PCom / posterior circulation | 4 |
- Higher total score = higher 5-year rupture risk; aids shared decision-making but does NOT replace clinical judgment
Treatment Thresholds & Management Algorithm
| Scenario | Recommendation | Rationale |
|---|---|---|
| ≥7 mm, anterior circulation | Generally treat (clip or coil) | Meaningful rupture risk; procedural risk justified |
| ≥5 mm, posterior circulation or PCom | Generally treat | Higher rupture rates at every size in posterior circulation |
| Symptomatic (any size) | Treat | Cranial nerve palsy, mass effect → indicates growth/impending rupture |
| Documented growth on serial imaging | Treat | Growth is a strong predictor of rupture |
| Irregular morphology (daughter sac, bleb) | Lower threshold to treat | Morphologic irregularity increases rupture risk independent of size |
| Family history of SAH (≥2 first-degree relatives) | Lower threshold to treat; screen family | 3–7× increased lifetime risk |
| <5–7 mm, anterior, asymptomatic | Observation with serial imaging | Low rupture risk; procedural risk may exceed natural history risk |
| Elderly with significant comorbidities | Observation unless symptomatic | Limited life expectancy; procedural risk outweighs benefit |
- If observing: Serial MRA or CTA at 6–12 months, then annually, then every 2–3 years if stable; any growth → treat
- Modifiable risk factor management: Smoking cessation (most important), blood pressure control, avoid cocaine/sympathomimetics
Board Pearls
- ISUIA: Anterior circulation <7 mm with no prior SAH has near-zero 5-year rupture risk — but most aneurysms that rupture in practice are <10 mm (ISUIA underestimates risk)
- Posterior circulation aneurysms rupture at higher rates at every size — lower treatment threshold (≥5 mm)
- Treat if: ≥7 mm anterior, ≥5 mm posterior, symptomatic, growing, irregular morphology, or strong family history
- PHASES score integrates population, hypertension, age, size, earlier SAH, and site for 5-year rupture risk prediction
AVM Management
Spetzler-Martin Grading System
- Most widely used grading system for cerebral AVMs; predicts surgical morbidity and mortality
- Three variables: AVM size, eloquence of adjacent brain, and pattern of venous drainage
| Feature | Grading | Points |
|---|---|---|
| Size (maximum diameter) | <3 cm (small) | 1 |
| 3–6 cm (medium) | 2 | |
| >6 cm (large) | 3 | |
| Eloquence of adjacent brain | Non-eloquent | 0 |
| Eloquent (sensorimotor cortex, language areas, visual cortex, hypothalamus, thalamus, brainstem, cerebellar peduncles, deep cerebellar nuclei) | 1 | |
| Venous drainage | Superficial only | 0 |
| Deep (any deep component) | 1 |
- Total score = Size + Eloquence + Venous drainage (range: 1–5)
| Grade | Score | Surgical Risk | Recommendation |
|---|---|---|---|
| I | 1 | Very low (~0–3% morbidity) | Surgery is treatment of choice |
| II | 2 | Low (~5% morbidity) | Surgery generally recommended |
| III | 3 | Moderate (~10–15% morbidity) | Multimodal therapy; individualized decision |
| IV | 4 | High (~20% morbidity) | Surgery generally NOT recommended; radiosurgery or observation |
| V | 5 | Very high (~30% morbidity) | Observation unless life-threatening hemorrhage |
Treatment Modalities
Microsurgical Resection
- Gold standard for Spetzler-Martin grade I–II; offers immediate and complete cure
- Complete obliteration rates >95% for low-grade AVMs
- Risk increases substantially with grade III and above
- Confirmatory post-operative DSA to document complete resection
Stereotactic Radiosurgery (Gamma Knife / CyberKnife)
- Best for small AVMs (<3 cm) in deep or eloquent locations not safely accessible surgically
- Obliteration rate: ~70–80% at 3 years for AVMs <3 cm; lower for larger AVMs
- Latency period: AVM remains patent and hemorrhage risk persists for 2–3 years until obliteration occurs
- Complications: Radiation-induced edema, radiation necrosis, delayed cyst formation
Endovascular Embolization
- Catheter-based injection of embolic agents (Onyx, NBCA glue) into AVM nidus/feeding arteries
- Rarely curative alone (complete obliteration in ~10–20%) — primarily used as adjunct
- Roles: Pre-surgical embolization to reduce nidus size and intraoperative bleeding; pre-radiosurgery volume reduction; targeted embolization of high-risk features (flow-related aneurysms)
- Complication rate: ~5–10% per session (hemorrhage from vessel perforation, ischemic stroke)
ARUBA Trial (A Randomized Trial of Unruptured Brain AVMs, 2014)
- Design: Multicenter RCT comparing interventional therapy (surgery, embolization, radiosurgery, or combination) vs. medical management alone for unruptured AVMs
- Results: Trial stopped early for futility — medical management was superior to intervention
- Primary endpoint (stroke or death): 10.1% medical vs. 30.7% intervention (HR 0.27; p < 0.0001)
- Functional outcome also favored medical management
- Controversy and limitations:
- Short follow-up (~33 months) — AVM natural history risk accumulates over a lifetime; results may not apply long-term
- Heterogeneous intervention group (surgery, radiosurgery, embolization lumped together)
- High embolization-only rate in intervention arm (~30%) despite embolization alone having lowest cure rates
- Low-grade AVMs (SM I–II) with low surgical risk may still benefit from surgery
- Selection bias — patients enrolled were those clinicians had equipoise about; sickest and easiest cases excluded
- Bottom line: ARUBA does NOT mean “never treat AVMs” — it suggests caution with intervention for unruptured AVMs, especially high-grade ones; low-grade surgical candidates may still benefit from surgery
Ruptured AVM Management
- Annual hemorrhage risk of untreated AVM: ~2–4% per year; higher after initial rupture (~4.5% in first year post-hemorrhage)
- Ruptured AVMs are generally treated (unlike ARUBA, which studied only unruptured AVMs)
- Treatment options for ruptured AVMs:
- Surgery: Preferred for low-grade (SM I–II) accessible AVMs; allows hematoma evacuation
- Multimodal approach: Embolization → surgery or embolization → radiosurgery for higher-grade AVMs
- Radiosurgery alone: For small, deep, or eloquent AVMs not safely resectable; accepts 2–3 year obliteration latency
- Timing after hemorrhage: Acute hematoma evacuation if life-threatening; definitive AVM treatment may be deferred 4–6 weeks to allow resolution of edema and inflammation
Board Pearls
- Spetzler-Martin grade = Size + Eloquence + Deep venous drainage (range 1–5); grades I–II are surgical; grade V is observation
- ARUBA: Medical management was superior for unruptured AVMs at ~33 months, but results are controversial — short follow-up, heterogeneous treatments, lifetime hemorrhage risk not captured
- Ruptured AVMs are generally treated; ARUBA does NOT apply to ruptured AVMs
- Radiosurgery takes 2–3 years for obliteration — hemorrhage risk persists during latency period
- Embolization is adjunctive, not curative alone (complete obliteration only ~10–20%)